More recently, clinical trials of inhibitors of immune checkpoint proteins, such as programmed cell death protein 1 (PD‐1) and PD ligand 1 (PD‐L1), have shown success in advanced bladder cancer in terms of response rate and durability 2, 9. Here, PDCD1 is linked to urinary bladder carcinoma.